Semaglutide vs Tirzepatide: Which Is Right for You?

Intro

If you’re considering GLP-1 treatment for weight loss, you’ve probably narrowed your choice down to two medications: semaglutide (the active ingredient in Ozempic® and Wegovy®) or tirzepatide (the active ingredient in Mounjaro® and Zepbound®).

Both work. Both produce significant weight loss. Both are taken as a weekly injection. From the outside, they can look almost interchangeable.

They’re not.

The two medications work on different hormone pathways, produce different average weight loss results, have different side effect profiles, and tend to suit different patients. Understanding the differences will help you have a more useful conversation with your provider — and increase the chances that whichever medication you start on is the one that actually works for your body.

This guide walks through what each medication does, how they compare in head-to-head clinical data, and how to think about which one might be right for you.

The Short Answer

If you want the quick version before diving into the detail:

• Semaglutide acts on one hormone pathway (GLP-1). It’s the older of the two, has more long-term safety data, and produces strong weight loss for most patients.
• Tirzepatide acts on two hormone pathways (GLP-1 and GIP). In head-to-head trials, it produces somewhat greater average weight loss than semaglutide, but it’s a newer molecule with less long-term data.

Both are effective. Tirzepatide produces larger weight loss on average. Semaglutide has a longer track record. Side effect tolerability varies individually — some patients do better on one, some on the other.

That’s the summary. The rest of this post explains why — and helps you think through which one likely fits you better.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a hormone your body produces in the small intestine in response to eating.

In the body, semaglutide binds to GLP-1 receptors in three primary places:

• The brain (specifically, the hypothalamus) — where it reduces hunger and increases the feeling of fullness
• The stomach — where it slows the rate at which food empties
• The pancreas — where it improves insulin response and lowers blood sugar

The combined effect is appetite reduction, longer-lasting fullness after meals, and more stable blood sugar — which together produce sustained weight loss in most patients.

Semaglutide was approved by the FDA for type 2 diabetes (as Ozempic) in 2017, and for chronic weight management (as Wegovy) in 2021. It now has nearly a decade of post-approval clinical data, including outcomes studies, long-term safety data, and cardiovascular benefit data.

For more on how semaglutide works in detail, see our foundational guide on how GLP-1 medications work.

How Tirzepatide Works

Tirzepatide is a dual agonist — it acts on two hormone receptors instead of one.

The first is GLP-1, the same pathway semaglutide targets. The second is GIP (glucose-dependent insulinotropic polypeptide), another gut hormone released in response to eating.

GIP is interesting because for years it was considered a less important hormone than GLP-1 in metabolic regulation. Then researchers discovered that activating GLP-1 and GIP together produces metabolic effects that exceed what either does alone — particularly around how the body processes fat and how cells respond to insulin.

Tirzepatide does what semaglutide does (appetite regulation, slowed digestion, improved insulin response) — and adds a second layer through GIP activation that appears to enhance fat metabolism, improve insulin sensitivity further, and produce greater weight loss on average.

Tirzepatide was approved by the FDA for type 2 diabetes (as Mounjaro) in 2022, and for chronic weight management (as Zepbound) in 2023. It’s the newer molecule, with several years of post-approval data and growing long-term outcome studies.

Head-to-Head: How Much Weight Loss Can You Expect?

This is the comparison most patients want answered. The clearest evidence comes from SURMOUNT-5, a head-to-head clinical trial published in 2025 that directly compared tirzepatide and semaglutide in patients with obesity.

In SURMOUNT-5, patients on tirzepatide for 72 weeks lost an average of 20.2% of their body weight. Patients on semaglutide over the same period lost an average of 13.7% of their body weight.

For a patient starting at 220 pounds, those averages translate roughly to:

• Tirzepatide: ~44 pounds lost
• Semaglutide: ~30 pounds lost

That’s a meaningful difference. Both medications produce strong weight loss; tirzepatide produces more on average.

Two important caveats:

One — these are averages. Individual results vary widely. Some patients on semaglutide lose more than the average tirzepatide patient. Some patients on tirzepatide lose less than the average semaglutide patient. Your biology, lifestyle, dose adherence, and treatment duration all influence the outcome.

Two — average doesn’t mean inevitable. A patient who tolerates tirzepatide poorly and stops at a low dose will lose less weight than a patient who tolerates semaglutide well and titrates to the maximum dose. Tolerance matters as much as the molecule.

Comparing the Side Effect Profiles

Both medications share similar side effect profiles, because both work through the same gut-brain mechanism. The most common side effects of either medication are gastrointestinal:

• Nausea
• Diarrhea or constipation
• Decreased appetite
• Fatigue (especially during dose increases)
• Indigestion or acid reflux
• Headaches

For most patients, these effects are most pronounced in the first 2–4 weeks of treatment and during dose increases. They typically diminish as the body adjusts.

That said, there are some patterns worth noting in how the two medications compare:

Tirzepatide tends to produce slightly more pronounced GI effects on average. This is consistent with its larger weight loss effect — the same mechanisms that drive appetite reduction also drive nausea. In SURMOUNT-5, tirzepatide patients reported nausea slightly more often than semaglutide patients, particularly during dose escalation.

Semaglutide’s side effects tend to be milder for most patients but can be more persistent. Some patients report nausea that lingers longer at higher doses, while tirzepatide patients more often report sharper but shorter side effect windows during dose changes.

Individual variation is the dominant factor. Some patients tolerate tirzepatide easily and find semaglutide nauseating. Others have the opposite experience. Genetics, baseline gut sensitivity, and how the dose is titrated all matter more than which molecule you’re on.

More serious side effects are similar for both:

• Pancreatitis
• Gallbladder issues, including gallstones
• Kidney problems, particularly with severe vomiting or dehydration
• Changes in vision (more common in patients with diabetes)
• Allergic reactions

Both medications carry a boxed warning about thyroid C-cell tumors based on rodent studies. Neither is recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

If you’ve had bad experiences with either medication’s side effects, switching to the other is a reasonable conversation to have with your provider. They’re not interchangeable, but they’re related enough that intolerance to one doesn’t always predict intolerance to the other.

How Each Medication Is Dosed

Both medications are weekly subcutaneous injections — typically self-administered at home, usually in the abdomen, thigh, or upper arm.

Semaglutide dosing for weight management (Wegovy schedule):

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance dose)

Tirzepatide dosing for weight management (Zepbound schedule):

• Weeks 1–4: 2.5 mg weekly
• Weeks 5–8: 5 mg weekly
• Weeks 9 onward: progressive increases up to 15 mg weekly (maintenance dose)

Both use a gradual dose-escalation schedule because starting at the maintenance dose would produce intolerable side effects in most patients. The slow titration allows the body to adjust.

Compounded versions of either medication may follow modified dosing schedules based on the formulation prepared by the compounding pharmacy and the protocol your provider designs. This is one reason why the provider relationship matters more than which molecule you choose — dose protocol affects results almost as much as the medication itself.

Which One Should You Choose?

Honest answer: the right choice depends on your individual situation, and it’s a conversation you should have with your provider. That said, here are the patterns that tend to emerge in clinical practice.

You may lean toward semaglutide if:

• You want the medication with the most long-term safety and outcomes data
• You’re sensitive to side effects and want to start with the medication that tends to have a milder GI profile
• You have cardiovascular risk factors — semaglutide has documented cardiovascular benefit data (the SELECT trial showed reduced cardiovascular events in patients with established cardiovascular disease)
• You’re starting at a lower starting weight or have a more modest weight loss goal
• Your insurance covers Ozempic or Wegovy but not Mounjaro or Zepbound

You may lean toward tirzepatide if:

• You’re starting at a higher weight or have a more significant weight loss goal
• You’ve tried semaglutide and didn’t see the results you hoped for
• You want the medication that produces the largest weight loss on average
• You have insulin resistance or metabolic syndrome — the dual GLP-1/GIP action appears particularly effective on insulin sensitivity
• Your insurance covers Mounjaro or Zepbound but not Ozempic or Wegovy

Either is reasonable if:

• You’re in the middle of these factors and don’t have a strong reason to lean one way
• You and your provider are comfortable starting with one and switching to the other if needed

This last point matters. Switching between semaglutide and tirzepatide is medically straightforward and reasonably common in clinical practice. If the first medication doesn’t produce your hoped-for results or causes intolerable side effects, switching to the other is a normal next step — not a treatment failure.

What About Switching Between Them?

A growing number of patients start on one GLP-1 medication and switch to the other based on response or tolerability. Here’s how it typically works.

Switching from semaglutide to tirzepatide — usually because weight loss has plateaued or the patient wants greater results. Your provider will typically discontinue semaglutide and start tirzepatide at a low dose (2.5 mg weekly), then titrate up. There’s no formal washout period required, though some providers recommend a one-week gap to let semaglutide clear.

Switching from tirzepatide to semaglutide — usually because of side effect intolerance, cost considerations, or insurance coverage changes. The transition follows a similar pattern: discontinue tirzepatide, start semaglutide at the low dose, titrate up.

Switching isn’t free of disruption — there’s typically a temporary period of reduced effectiveness while the new medication titrates up. But for many patients, the right medication is the second one they try, not the first.

What Happens Long-Term?

Both medications are designed for long-term use, not short-term intervention.

Studies on semaglutide (the STEP trials) and tirzepatide (the SURMOUNT trials) consistently show that stopping either medication leads to significant weight regain — often two-thirds or more of the lost weight returning within 12 months of discontinuation. This is because the medications don’t permanently change your body’s set point; they hold a new lower weight in place while you’re on them.

For most patients, the clinical conversation is shifting from “how long do I need to take this?” to “how do I plan to stay on this safely and sustainably?” — including discussions of dose reduction, lifestyle support, and long-term monitoring.

This is part of why the ongoing provider relationship matters more than the specific molecule you start with. The right medication for the long term is the one you can stay on, tolerate, afford, and combine with lifestyle changes that support sustained results.

How to Get Started

If you’re considering either medication, the next step is a conversation with a licensed provider who can review your medical history, your goals, and your insurance situation, and recommend which medication fits your case.

At Provn, the consultation process is online:

1. Take a short medical questionnaire (about 3 minutes)
2. A licensed U.S. physician reviews your information, usually within 24 hours
3. If treatment is appropriate, your prescription ships to your door in plain, unmarked, temperature-controlled packaging
4. You have ongoing access to your provider for dose adjustments, side effect questions, and long-term planning

You can start with compounded semaglutide here, explore compounded tirzepatide here, or learn more about the branded options on our Ozempic, Wegovy, Mounjaro, and Zepbound pages.

The Takeaway

Semaglutide and tirzepatide are both effective GLP-1 medications for weight management, and the choice between them is genuinely individual.

Tirzepatide produces greater weight loss on average and adds a second hormone pathway. Semaglutide has more long-term data, documented cardiovascular benefit, and a slightly milder side effect profile for many patients. Both are reasonable starting points. Many patients end up trying both at different points in their treatment.

The right next step isn’t choosing between them in the abstract — it’s a conversation with a licensed provider who can help you weigh the factors specific to your situation.

Take the quiz to get started.

Frequently Asked Questions

Is tirzepatide really more effective than semaglutide?

On average, yes — head-to-head trial data (SURMOUNT-5) shows tirzepatide produces greater weight loss. But “on average” hides significant individual variation. Plenty of patients lose more on semaglutide than the average tirzepatide patient. The medication that’s most effective for you depends on how your body responds, which often isn’t predictable until you try one.

Are the side effects worse on tirzepatide?

Slightly, on average — particularly during dose escalation. But individual variation is the dominant factor. Some patients tolerate tirzepatide easily and find semaglutide nauseating. Others have the opposite experience. Both medications use gradual dose titration to minimize side effects, and most patients find that effects diminish over the first few weeks of treatment.

Can I switch from semaglutide to tirzepatide if it’s not working?

Yes. Switching between GLP-1 medications is medically straightforward and reasonably common. Your provider will discontinue the current medication and start the new one at the low dose, titrating up over several weeks. Many patients who didn’t see hoped-for results on the first medication respond better to the second.

Can I take both at the same time?

No. Semaglutide and tirzepatide both act on GLP-1 receptors and combining them would produce overlapping effects with significantly elevated side effect risk. Patients use one or the other, not both.

Which is better for diabetes?

Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Tirzepatide produces somewhat greater A1C reduction in clinical trials, but semaglutide has longer outcomes data including cardiovascular benefit. For diabetes specifically, the choice is best made with a provider who can review your full clinical picture.